|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Cytomx Therapeutics, Inc. (CTMX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
65,160,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing an antibody-based therapeutics created using its Probody® therapeutic technology platform. Co.'s products include: Praluzatamab ravtansine, which is an activated antibody-drug conjugates directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues; CX-2029, which opens a therapeutic window for targeting CD71; Pacmilimab, which is a Probody therapeutic against PD-L1, a clinically and commercially validated cancer target; and BMS-986249 and BMS-986288, which is the Probody versions of ipilimumab.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
47,819 |
75,591 |
103,916 |
162,805 |
| Total Sell Value |
$99,726 |
$138,068 |
$174,902 |
$267,502 |
| Total People Sold |
5 |
5 |
5 |
8 |
| Total Sell Transactions |
5 |
10 |
14 |
26 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ray Debanjan |
Chief Financial Officer |
• – – |
2018-03-01 |
4 |
OE |
$1.26 |
$16,379 |
D/D |
13,000 |
17,741 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2018-03-01 |
4 |
AS |
$29.43 |
$576,141 |
D/D |
(19,578) |
4,643 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2018-03-01 |
4 |
OE |
$0.95 |
$26,825 |
D/D |
19,578 |
24,221 |
|
- |
|
| Gluck Frederick W |
Director |
– • – |
2018-02-28 |
4 |
AS |
$30.00 |
$114,570 |
I/I |
(3,819) |
292,824 |
|
- |
|
| Humphrey Rachel |
Chief Medical Officer |
• – – |
2018-02-28 |
4 |
AS |
$30.00 |
$715,200 |
D/D |
(23,840) |
30,234 |
|
- |
|
| Humphrey Rachel |
Chief Medical Officer |
• – – |
2018-02-28 |
4 |
OE |
$6.61 |
$157,694 |
D/D |
23,840 |
54,074 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2018-02-01 |
4 |
AS |
$26.69 |
$68,010 |
D/D |
(2,548) |
4,741 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2018-01-05 |
4 |
AS |
$25.01 |
$163,215 |
D/D |
(6,526) |
4,643 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2018-01-05 |
4 |
OE |
$1.13 |
$7,400 |
D/D |
6,526 |
11,169 |
|
- |
|
| Gluck Frederick W |
Director |
– • – |
2018-01-05 |
4 |
AS |
$25.01 |
$250,078 |
I/I |
(10,000) |
296,643 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2018-01-02 |
4 |
AS |
$21.04 |
$274,614 |
D/D |
(13,052) |
4,643 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2018-01-02 |
4 |
OE |
$1.13 |
$14,800 |
D/D |
13,052 |
17,695 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2018-01-02 |
4 |
AS |
$21.11 |
$52,775 |
D/D |
(2,500) |
7,289 |
|
- |
|
| Gluck Frederick W |
Director |
– • – |
2017-12-26 |
4 |
AS |
$22.29 |
$111,426 |
I/I |
(5,000) |
306,643 |
|
- |
|
| Humphrey Rachel |
Chief Medical Officer |
• – – |
2017-12-15 |
4 |
OE |
$6.61 |
$99,994 |
D/D |
15,117 |
30,234 |
|
- |
|
| Kavanaugh William Michael |
CSO, Head Res.&Non-Clin. Dev. |
• – – |
2017-12-08 |
4 |
OE |
$1.57 |
$8,079 |
D/D |
5,130 |
19,047 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2017-12-01 |
4 |
AS |
$20.58 |
$51,450 |
D/D |
(2,500) |
9,789 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-12-01 |
4 |
AS |
$20.60 |
$295,404 |
D/D |
(14,340) |
4,643 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-12-01 |
4 |
OE |
$0.95 |
$15,486 |
D/D |
14,340 |
18,983 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2017-11-30 |
4 |
A |
$12.15 |
$1,980 |
D/D |
163 |
12,289 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-11-30 |
4 |
A |
$12.15 |
$4,834 |
D/D |
398 |
4,643 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2017-11-01 |
4 |
AS |
$20.00 |
$50,000 |
D/D |
(2,500) |
12,126 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-11-01 |
4 |
AS |
$19.86 |
$284,832 |
D/D |
(14,342) |
4,245 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2017-11-01 |
4 |
OE |
$0.95 |
$13,553 |
D/D |
14,342 |
18,587 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2017-10-18 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,000,000) |
3,320,348 |
|
- |
|
286 Records found
|
|
Page 6 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
